Skip to main content

$4.8B Roche-Spark deal delayed, once again

Roche and Spark Therapeutics are delaying their $4.8 billion deal for a third time to again give federal regulators more time to review the proposed sale of the Philadelphia gene therapy company.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.